Oncology Corporate Profile
OSE Pharma is a European cancer immunotherapy company with a specific T cytotoxic technology, focused on developing multi-epitopes therapeutic cancer vaccines. OSE Pharma's lead product, OSE-2101 is about to enter a pivotal Phase 3 study in patients with non small cell lung cancer (NSCLC), is ready for Phase 2 development in other cancer indications (ovarian, colon, breast, prostate) and is a suitable candidate for immune combination therapy. OSE-2101 targets five tumor associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. OSE-2101 contains ten optimized epitopes, derived from these five tumor antigens, which generate strong specific T cytotoxic responses that lead to the body's immune system killing tumor cells expressing the tumor antigens.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|OSE2101||immunotherapy||Non Small Cell Lung Cancer (NSCLC)||III|